BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1319-1327

  Bojarska Junak, Agnieszka ^a   Hus, Iwona ^a   Chocholska, Sylwia ^a   Wasik Szczepanek, Ewa ^a   Sieklucka, Małgorzata ^a   Dmoszyńska, Anna ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

APRIL; B CLL; BAFF; CD38; ZAP 70

Indexed keywords

ADAM PROTEIN; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CD38 ANTIGEN; LIPOPROTEIN LIPASE; PROTEIN ADAM29; PROTEIN KINASE ZAP 70; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL LEVEL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; SURVIVORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 67649354466     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.030     Document Type: Article

References (28)

1. Mackay F., Silveira P.A., and Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 19 (2007) 327-336
2. Bossen C., and Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18 (2006) 263-275
3. Tangye S.G., Bryant V.L., Cuss A.K., and Good K.L. BAFF, APRIL and human B cell disorders. Semin Immunol 18 (2006) 305-317
4. Planelles L., Carvalho-Pinto C.E., Hardenberg G., Smaniotto S., Savino W., Gómez-Caro R., et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6 (2004) 399-408
5. Kern C., Cornuel J.F., Billard C., Tang R., Rouillard D., Stenou V., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103 (2004) 679-688
6. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
7. Crespo M., Bosch F., Villamor N., Bellosillo B., Colomer D., Rozman M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
8. Durig J., Nuckel H., Cremer M., Fuhrer A., Halfmeyer K., Fandrey J., et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17 (2003) 2426-2434
9. Heintel D., Kienle D., Shehata M., Kröber A., Kroemer E., Schwarzinger I., et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 19 (2005) 1216-1223
10. Oppezzo P., Vasconcelos Y., Settegrana C., Jeannel D., Vuillier F., Legarff-Tavernier M., et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 106 (2005) 650-657
11. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., O'Brien S., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
12. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., and Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
13. Bojarska-Junak A., Rolinski J., and Kawiak J. Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol 43 (2005) 19-23
14. Bojarska-Junak A., Giannopoulos K., Kowal M., Dmoszynska A., and Rolinski J. Comparison of methods for determining zeta-chain associated protein-70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin Cytom 70 (2006) 293-301
15. Shanafelt T.D., and Call T.G. Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 79 (2004) 388-398
16. Haiat S., Billard C., Quiney C., Ajchenbaum-Cymbalista F., and Kolb J.P. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118 (2006) 281-292
17. Planelles L., Castillo-Gutiérrez S., Medema J.P., Morales-Luque A., Merle-Béral H., and Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 92 (2007) 1284-1285
18. Novak A.J., Grote D.M., Ziesmer S.C., Kline M.P., Manske M.K., Slager S., et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 24 (2006) 983-987
19. Novak A.J., Bram R.J., Kay N.E., and Jelinek D.F. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 100 (2002) 2973-2979
20. Novak A.J., Darce J.R., Arendt B.K., Harder B., Henderson K., Kindsvogel W., et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103 (2004) 689-694
21. Hansen A., Lipsky P.E., and Dörner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3 (2007) 56156-56159
22. Smedby K.E., Baecklund E., and Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 15 (2006) 2069-2077
23. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33 (2006) 230-239
24. Mackay F., Schneider P., Rennert P., and Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21 (2003) 231-264
25. Yan M., Wang H., Chan B., Roose-Girma M., Erickson S., Baker T., et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2 (2001) 638-643
26. von Bülow G.U., van Deursen J.M., and Bram R.J. Regulation of the T-independent humoral response by TACI. Immunity 14 (2001) 573-582
27. Seshasayee D., Valdez P., Yan M., Dixit V.M., Tumas D., and Grewal I.S. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18 (2003) 279-288
28. Moreaux J., Cremer F.W., Reme T., Raab M., Mahtouk K., Kaukel P., et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106 (2005) 1021-1030